Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease.

Molero AE, Arteaga-Bracho EE, Chen CH, Gulinello M, Winchester ML, Pichamoorthy N, Gokhan S, Khodakhah K, Mehler MF.

Proc Natl Acad Sci U S A. 2016 May 17;113(20):5736-41. doi: 10.1073/pnas.1603871113. Epub 2016 May 2.

2.

Influence of cortical synaptic input on striatal neuronal dendritic arborization and sensitivity to excitotoxicity in corticostriatal coculture.

Buren C, Tu G, Parsons MP, Sepers MD, Raymond LA.

J Neurophysiol. 2016 Aug 1;116(2):380-90. doi: 10.1152/jn.00933.2015. Epub 2016 Apr 27.

3.

Real-time imaging of glutamate clearance reveals normal striatal uptake in Huntington disease mouse models.

Parsons MP, Vanni MP, Woodard CL, Kang R, Murphy TH, Raymond LA.

Nat Commun. 2016 Apr 7;7:11251. doi: 10.1038/ncomms11251.

4.

Nicotine Modifies Corticostriatal Plasticity and Amphetamine Rewarding Behaviors in Mice(1,2,3).

Storey GP, Gonzalez-Fernandez G, Bamford IJ, Hur M, McKinley JW, Heimbigner L, Minasyan A, Walwyn WM, Bamford NS.

eNeuro. 2016 Feb 2;3(1). pii: ENEURO.0095-15.2015. doi: 10.1523/ENEURO.0095-15.2015. eCollection 2016 Jan-Feb.

5.

Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice.

Valenza M, Chen JY, Di Paolo E, Ruozi B, Belletti D, Ferrari Bardile C, Leoni V, Caccia C, Brilli E, Di Donato S, Boido MM, Vercelli A, Vandelli MA, Forni F, Cepeda C, Levine MS, Tosi G, Cattaneo E.

EMBO Mol Med. 2015 Dec;7(12):1547-64. doi: 10.15252/emmm.201505413.

6.

Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice.

Pancani T, Foster DJ, Moehle MS, Bichell TJ, Bradley E, Bridges TM, Klar R, Poslusney M, Rook JM, Daniels JS, Niswender CM, Jones CK, Wood MR, Bowman AB, Lindsley CW, Xiang Z, Conn PJ.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14078-83. doi: 10.1073/pnas.1512812112. Epub 2015 Oct 27.

7.

A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease.

Puigdellívol M, Cherubini M, Brito V, Giralt A, Suelves N, Ballesteros J, Zamora-Moratalla A, Martín ED, Eipper BA, Alberch J, Ginés S.

Hum Mol Genet. 2015 Dec 20;24(25):7265-85. doi: 10.1093/hmg/ddv426. Epub 2015 Oct 12.

8.

Ca(2+) handling in isolated brain mitochondria and cultured neurons derived from the YAC128 mouse model of Huntington's disease.

Pellman JJ, Hamilton J, Brustovetsky T, Brustovetsky N.

J Neurochem. 2015 Aug;134(4):652-67. doi: 10.1111/jnc.13165. Epub 2015 Jun 4.

9.

Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases.

Gardoni F, Bellone C.

Front Cell Neurosci. 2015 Mar 2;9:25. doi: 10.3389/fncel.2015.00025. eCollection 2015. Review.

10.

Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.

Indersmitten T, Tran CH, Cepeda C, Levine MS.

J Neurophysiol. 2015 Apr 1;113(7):2953-66. doi: 10.1152/jn.01056.2014. Epub 2015 Feb 11.

11.

Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.

Wong MY, Borgkvist A, Choi SJ, Mosharov EV, Bamford NS, Sulzer D.

Neuroscience. 2015 Apr 2;290:594-607. doi: 10.1016/j.neuroscience.2015.01.022. Epub 2015 Jan 28.

12.

Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation.

Biagioli M, Ferrari F, Mendenhall EM, Zhang Y, Erdin S, Vijayvargia R, Vallabh SM, Solomos N, Manavalan P, Ragavendran A, Ozsolak F, Lee JM, Talkowski ME, Gusella JF, Macdonald ME, Park PJ, Seong IS.

Hum Mol Genet. 2015 May 1;24(9):2442-57. doi: 10.1093/hmg/ddv006. Epub 2015 Jan 8.

13.
14.

Studies on the Q175 Knock-in Model of Huntington's Disease Using Functional Imaging in Awake Mice: Evidence of Olfactory Dysfunction.

Ferris CF, Kulkarni P, Toddes S, Yee J, Kenkel W, Nedelman M.

Front Neurol. 2014 Jun 30;5:94. doi: 10.3389/fneur.2014.00094. eCollection 2014.

15.

Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease.

Galvan L, André VM, Wang EA, Cepeda C, Levine MS.

J Huntingtons Dis. 2012;1(1):17-25. doi: 10.3233/JHD-2012-120009. Review.

16.

Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits.

McKinstry SU, Karadeniz YB, Worthington AK, Hayrapetyan VY, Ozlu MI, Serafin-Molina K, Risher WC, Ustunkaya T, Dragatsis I, Zeitlin S, Yin HH, Eroglu C.

J Neurosci. 2014 Jul 9;34(28):9455-72. doi: 10.1523/JNEUROSCI.4699-13.2014.

17.

The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Chopra R, Shakkottai VG.

Neurotherapeutics. 2014 Oct;11(4):751-63. doi: 10.1007/s13311-014-0289-7. Review.

18.

The role of dopamine in Huntington's disease.

Cepeda C, Murphy KP, Parent M, Levine MS.

Prog Brain Res. 2014;211:235-54. doi: 10.1016/B978-0-444-63425-2.00010-6. Review.

19.

Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington's Disease Mice.

Botelho EP, Wang E, Chen JY, Holley S, Andre V, Cepeda C, Levine MS.

PLoS Curr. 2014 May;6. pii: ecurrents.hd.34957c4f8bd7cb1f5ec47381dfc811c3. doi: 10.1371/currents.hd.34957c4f8bd7cb1f5ec47381dfc811c3. Erratum in: PLoS Curr. 2017 Jul 11;9:.

20.

Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease.

Kolodziejczyk K, Parsons MP, Southwell AL, Hayden MR, Raymond LA.

PLoS One. 2014 Apr 11;9(4):e94562. doi: 10.1371/journal.pone.0094562. eCollection 2014.

Supplemental Content

Support Center